Glenmark Pharmaceuticals has informed that it attached media release received from Ichnos Sciences Inc. (wholly owned subsidiary of the Company) regarding Ichnos Sciences Enters Licensing Agreement for OX40 Antagonist Monoclonal Antibody Portfolio with Astria Therapeutics.
The above information is a part of company’s filings submitted to BSE.